Companion animal oncology is emerging as one of the highest-growth sub-segments in veterinary medicine. Cancer is now the leading cause of death in dogs over the age of 10, with approximately 6 million new canine cancer diagnoses annually in the U.S. alone. IDEXX launched IDEXX Cancer Dx in 2025 for canine lymphoma — a simple blood test screening — and plans to expand the panel to canine mast cell tumors. PetDx's OncoK9 liquid biopsy detects 30+ cancer types from a single blood draw. Therapeutic innovation includes Stelfonta (tigilanol tiglate) for mast cell tumors, Tanovea (rabacfosadine) for canine lymphoma, and emerging mAb pipelines from Zoetis, Elanco-Kindred, and Aratana. The companion animal oncology market is forecast to grow at high-double-digit rates through 2030.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Companion Animal Oncology Market Size, Growth and Forecast 2025-2030
• Canine Lymphoma — Screening, Diagnostics, and Therapeutic Pipelines
• Mast Cell Tumors — Diagnostics and Targeted Therapeutics
• Solid Tumors — Osteosarcoma, Hemangiosarcoma, Mammary Tumors
• Feline Cancer — Squamous Cell Carcinoma, Lymphoma, Other Indications
• Liquid Biopsy and Genomic Cancer Testing — PetDx, IDEXX Cancer Dx
• Targeted Therapeutics — Tanovea, Stelfonta, Palladia, mAb Pipelines
• Immunotherapy and Cancer Vaccines — Emerging Pipelines and Approaches
• Veterinary Oncology Specialty Practice Network and Referral Dynamics
• Investment and Partnership Opportunities — Licensing, Co-Development
• Market Challenges and Risks — Pricing, Owner Willingness to Treat, Adoption
Table of Contents
1. Executive Summary
2. Market Overview
3. Companion Animal Oncology Market Size, Growth and Forecast 2025-2030
4. Canine Lymphoma
5. Mast Cell Tumors
6. Solid Tumors
7. Feline Cancer
8. Liquid Biopsy and Genomic Testing
9. Targeted Therapeutics
10. Immunotherapy and Cancer Vaccines
11. Veterinary Oncology Specialty Practice Network
12. Regional Analysis
13. Market Challenges and Risks
14. Competitive Landscape
15. Strategic Conclusions and Recommendations
16. Appendix
List of Tables
Table 1. Companion Animal Oncology Market Size and Forecast 2025-2030
Table 2. Cancer Incidence by Indication and Species 2025
Table 3. Canine Lymphoma Diagnostic and Therapeutic Pipeline by Supplier
Table 4. Mast Cell Tumor Therapeutics — Stelfonta and Pipeline Candidates
Table 5. Liquid Biopsy and Genomic Test Sales — PetDx, IDEXX Cancer Dx
Table 6. Targeted Therapeutic Sales — Tanovea, Palladia, Stelfonta 2023-2025
Table 7. mAb and Immunotherapy Pipeline by Supplier 2025
Table 8. Veterinary Oncology Practice Group Network Coverage
Table 9. Investment and Licensing Activity in Veterinary Oncology 2023-2026
Table 10. Competitive Positioning by Indication and Modality
Companies Profiled
Aratana Therapeutics
AskBio
Elanco Animal Health
IDEXX Laboratories
Kindred Biosciences
Merck Animal Health
One Health Company
PetDx
Virbac
VolitionRx
Zoetis
